• No results found

VU Research Portal

N/A
N/A
Protected

Academic year: 2021

Share "VU Research Portal"

Copied!
3
0
0

Bezig met laden.... (Bekijk nu de volledige tekst)

Hele tekst

(1)

VU Research Portal

The intestinal microbiota disrupted & restored

van Beurden, Y.H.

2017

document version

Publisher's PDF, also known as Version of record

Link to publication in VU Research Portal

citation for published version (APA)

van Beurden, Y. H. (2017). The intestinal microbiota disrupted & restored: On Clostridium difficile infection and

fecal donation.

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. • Users may download and print one copy of any publication from the public portal for the purpose of private study or research. • You may not further distribute the material or use it for any profit-making activity or commercial gain

• You may freely distribute the URL identifying the publication in the public portal ?

Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

E-mail address:

vuresearchportal.ub@vu.nl

(2)

TABLE OF CONTENTS

Chapter 1 General introduction and outline of thesis

Part I An outbreak of Clostridium difficile infection

Chapter 2 An outbreak of Clostridium difficile ribotype 027 associated with length of stay in the intensive care unit and use of selective decontamination of the digestive tract: a case control study

PLOS ONE 2016

Chapter 3 Host factors are more important in predicting recurrent Clostridium

difficile infection than ribotype and use of antibiotics Clinical Microbiology and Infection 2017

Chapter 4 Cost-analysis of an outbreak of Clostridium difficile infection in a tertiary care center

Journal of Hospital Infection 2016

Part II Prediction tools for complications after Clostridium difficile infection

Chapter 5 External validation of three prediction tools for patients at risk of a complicated course of Clostridium difficile infection: disappointing in outbreak setting

Infection Control and Hospital Epidemiology 2017

Chapter 6 Predicting recurrence of Clostridium difficile infection by on-site profiling of fecal volatile organic compounds

Submitted

Part III Fecal Microbiota Transplantation for Clostridium difficile infection

Chapter 7 Complications, effectiveness, and long-term follow up of fecal microbiota transfer by nasoduodenal tube for treatment of recurrent

Clostridium difficile infection

(3)

Chapter 8 Current challenges in the treatment of severe Clostridium difficile infection: early treatment potential of fecal microbiota

transplantation

Therapeutic Advances in Gastroenterology 2017

Chapter 9 Serial microbiota analysis after fecal microbiota transplantation in a child with Down syndrome

Journal of Pediatric Infectious Disease 2017

Part IV Fecal Microbiota Transplantation: other indications and the development of the Netherlands Donor Feces Bank

Chapter 10 Fecal microbiota transplantation: indications in perspective

Nederlands Tijdschrift voor Geneeskunde 2017

Chapter 11 Fecal microbiota transplantation as treatment for post-infection and antibiotic induced irritable bowel syndrome: a pilot study

Submitted

Chapter 12 Serendipity in refractory celiac disease: full recovery of duodenal villi and clinical symptoms after fecal microbiota transfer

Journal of Gastrointestinal and Liver Disease 2016

Chapter 13 How to: Establish and run a stool bank?

Clinical Microbiology and Infection 2017

Part V Discussion and summary

Chapter 14 Summary of results and general discussion Chapter 15 Dutch summary / Nederlandse samenvatting

Appendices

Referenties

GERELATEERDE DOCUMENTEN

Demographic data and risk factors for patients with Clostridium difficile–associated disease (CDAD) due to ribotype 027, compared with patients with CDAD due to non-027

License: Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden. Downloaded

For MLVA, the collection of 51 isolates was expanded with 11 human type 078/toxinotype V isolates that were available from other countries and another 3 Dutch type 078/toxinotype

Note: To cite this publication please use the final published version

Recently, a retrospective study analysing risk factors for CDI in an endemic setting in the USA reported an incidence rate of CDI of 106 per 10,000 hospital admissions, which is

difficile infection caused by the virulent NAP-1/027 strain: increased production of toxins A and B, fluoroquinolone resistance, and production of binary

Note: To cite this publication please use the final published version

Note: To cite this publication please use the final published version